FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and experimental medicine, namely to the use of deferoxamine, which is an iron chelator, as an agent reducing cardiac contractile dysfunction in an experimental model of takotsubo syndrome.
EFFECT: invention widens the range of products used for the proposed purpose.
1 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SOLUTION THAT INCREASES THE RESISTANCE OF THE HEART TO STRESS DAMAGE | 2021 |
|
RU2775779C1 |
| METHOD FOR EVALUATING THE STATE OF MYOCARDIUM IN CARDIOSURGICAL INTERVENTIONS UNDER CONDITIONS OF CARDIOPLEGIC PROTECTION | 2017 |
|
RU2651364C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING REPEATED REMODELING OF THE LEFT VENTRICULAR MYOCARDIUM WITHIN 12 MONTHS AFTER SURGICAL TREATMENT OF ISCHEMIC CARDIOMYOPATHY | 2020 |
|
RU2745473C1 |
| METHOD FOR DETERMINING MITOCHONDRIAL MYOCARDIAL DYSFUNCTION FOLLOWING CARDIAC TRANSPLANTATION USING RADIONUCLIDE METHOD | 2018 |
|
RU2687584C1 |
| METHOD OF PREDICTING AN INCREASED RISK OF A COMPLICATED COURSE OF THE EARLY POSTOPERATIVE PERIOD IN PATIENTS WITH ISCHEMIC CARDIOMYOPATHY AT THE PREOPERATIVE STAGE | 2022 |
|
RU2801159C1 |
| METHOD OF TREATING PATIENTS WITH MYOCARDIAL INFARCTION | 2007 |
|
RU2381795C2 |
| METHOD OF CARDIOPROTECTIVE ACTIVITY ESTIMATION OF PHARMACOLOGICAL FACILITIES | 2017 |
|
RU2643104C1 |
| METHOD FOR NON-INVASIVE ASSESSMENT OF LEFT VENTRICULAR CONTRACTILITY RESERVE IN PATIENTS WITH ISCHEMIC CARDIOMYOPATHY | 2018 |
|
RU2695902C1 |
| AGENT FOR RELIEVING POSTINFARCTION MYOCARDIAL REMODELING | 2022 |
|
RU2830221C2 |
| METHOD FOR TREATING VENTRICULAR EXTRASYSTOLE THE CASES OF MYOCARDIAL INFARCTION | 2000 |
|
RU2197241C2 |
